Fmoc-D-Asp-ODmb
Need Assistance?
  • US & Canada:
    +
  • UK: +

Fmoc-D-Asp-ODmb

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
D-Amino Acids
Catalog number
BAT-015043
CAS number
200335-63-3
Molecular Formula
C28H27NO8
Molecular Weight
505.53
Fmoc-D-Asp-ODmb
IUPAC Name
(3R)-4-[(2,4-dimethoxyphenyl)methoxy]-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid
Synonyms
Fmoc-D-aspartic acid 1-(2,4-dimethoxybenzyl) ester; D-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 1-[(2,4-dimethoxyphenyl)methyl] ester; (3R)-4-[(2,4-Dimethoxybenzyl)oxy]-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-oxobutanoic acid
Purity
99%
Density
1.303±0.06 g/cm3 (Predicted)
Boiling Point
728.1±60.0°C (Predicted)
Storage
Store at -20°C
InChI
InChI=1S/C28H27NO8/c1-34-18-12-11-17(25(13-18)35-2)15-36-27(32)24(14-26(30)31)29-28(33)37-16-23-21-9-5-3-7-19(21)20-8-4-6-10-22(20)23/h3-13,23-24H,14-16H2,1-2H3,(H,29,33)(H,30,31)/t24-/m1/s1
InChI Key
ODIFVCRSTRBDDR-XMMPIXPASA-N
Canonical SMILES
COC1=CC(=C(C=C1)COC(=O)C(CC(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)OC

Fmoc-D-Asp-ODmb, a protected D-aspartic acid derivative pivotal in peptide synthesis and biochemical research, finds diverse applications. Here are four key applications presented with high perplexity and burstiness:

Peptide Synthesis: Leading the charge in solid-phase peptide synthesis (SPPS), Fmoc-D-Asp-ODmb emerges as a critical player in introducing D-aspartic acid residues into peptides. The strategic Fmoc protecting group enables selective deprotection during synthesis, ensuring meticulous sequence assembly. This precision is paramount in crafting peptides with tailored structural and functional attributes for both research exploration and therapeutic endeavors.

Drug Development: Delving into pharmaceutical realms, Fmoc-D-Asp-ODmb stands as a linchpin for synthesizing peptides housing D-aspartic acid—a feature endowing unique biological activity and stability. These D-peptides wield the potential to bolster drug efficacy and fortify resistance against proteolytic degradation. This application serves as a cornerstone in spearheading the creation of novel peptide-based therapeutics furnished with enhanced pharmacokinetic profiles.

Protein Engineering: In the dynamic arena of protein engineering, Fmoc-D-Asp-ODmb takes center stage as a conduit for probing protein folding, structure, and function. By integrating D-aspartic acid residues into proteins or peptides, researchers plunge into unraveling the repercussions on protein stability and interactions. This acumen plays a pivotal role in sculpting proteins endowed with bespoke characteristics for varied biotechnological applications.

Biochemical Research: Unveiling its prowess in biochemical spheres, Fmoc-D-Asp-ODmb emerges as a potent tool for manipulating peptide properties and exploring their interplay with biomolecules. It empowers researchers to fashion peptides with modified conformations and binding affinities, paving the way for nuanced insights into molecular recognition processes. This application stands as a cornerstone in enriching our comprehension of biomolecular interactions and fostering the development of cutting-edge biomolecular sensors.

1. Asparagine coupling in Fmoc solid phase peptide synthesis
H Gausepohl, M Kraft, R W Frank Int J Pept Protein Res. 1989 Oct;34(4):287-94. doi: 10.1111/j.1399-3011.1989.tb01576.x.
To investigate side reactions during the activation of side chain unprotected asparagine in Fmoc-solid phase peptide synthesis the peptide Met-Lys-Asn-Val-Pro-Glu-Pro-Ser was synthesized using different coupling conditions for introduction of the asparagine residue. Asparagine was activated by DCC/HOBt, BOP (Castro's reagent) or introduced as the pentafluorophenyl ester. The resulting peptide products were analyzed by HPLC, mass spectrometry and Edman degradation. In the crude products varying amounts of beta-cyano alanine were found, which had been formed by dehydration of the side chain amide during carboxyl activation of Fmoc-asparagine. A homogeneous peptide was obtained by using either side chain protected asparagine derivatives with BOP mediated activation or by coupling of Fmoc-Asn-OPfp. Fmoc-Asn(Mbh)-OH and Fmoc-Asn(Tmob)-OH were coupled rapidly and without side reactions with BOP. For the side chain protected derivatives the coupling was as fast as that of other Fmoc-amino acid derivatives, whereas couplings of Fmoc-Asn-OH proceed more slowly. However, during acidolytic cleavage both protection groups, Mbh and Tmob, generate carbonium ions which readily alkylate tryptophan residues in a peptide. Tryptophan modification was examined using the model peptide Asn-Trp-Asn-Val-Pro-Glu-Pro-Ser. Alkylation could be reduced by addition of scavengers to the TFA during cleavage and side chain deprotection. A homogeneous peptide containing both, asparagine and tryptophan, was obtained only by coupling of Fmoc-Asn-OPfp.
2. Solid-phase synthesis and applications of N-(S-acetylmercaptoacetyl) peptides
J W Drijfhout, W Bloemhoff, J T Poolman, P Hoogerhout Anal Biochem. 1990 Jun;187(2):349-54. doi: 10.1016/0003-2697(90)90468-o.
The reagent pentafluorophenyl S-acetylmercaptoacetate was used to modify the N-terminus of resin-bound side-chain-protected peptides. The modification was carried out in an automated cycle in the final stage of fluorenylmethoxycarbonyl (Fmoc)/polyamide-mediated solid-phase synthesis. Side-chain deprotection and cleavage from the resin with aqueous trifluoroacetic acid gave the N-(S-acetylmercaptoacetyl) peptides. The S-acetylmercaptoacetyl peptides were transformed into reactive thiol-containing peptides by incubation with hydroxylamine at neutral pH. The S-deacetylation was performed in the presence of a sulfhydryl-reactive compound (or intramolecular group) to enable immediate capture of the sensitive thiol. Three applications were investigated. An S-acetylmercaptoacetyl peptide, containing a sequence of a meningococcal membrane protein, was incubated with hydroxylamine in the presence of 5-(iodoacetamido)fluorescein to give the corresponding fluorescein-labeled peptide in 62% yield. The same peptide was also S-deacetylated in the presence of bromoacetylated poly-L-lysine to afford a peptide/polylysine conjugate. Finally, a peptide corresponding to a sequence of herpes simplex virus glycoprotein D was prepared. This peptide, containing an N-terminal-S-acetylmercaptoacetyl group and an additional C-terminal S-(3-nitro-2-pyridinesulfenyl)cysteine residue, was converted into a cyclic disulfide peptide (20%).
3. Solid-Phase Total Synthesis of Bacitracin A
Jinho Lee, John H. Griffin, Thalia I. Nicas J Org Chem. 1996 Jun 14;61(12):3983-3986. doi: 10.1021/jo960580b.
An efficient solid-phase method for the total synthesis of bacitracin A is reported. This work was undertaken in order to provide a general means of probing the intriguing mode of action of the bacitracins and exploring their potential for use against emerging drug-resistant pathogens. The synthetic approach to bacitracin A involves three key features: (1) linkage to the solid support through the side chain of the L-asparaginyl residue at position 12 (L-Asn(12)), (2) cyclization through amide bond formation between the alpha-carboxyl of L-Asn(12) and the side chain amino group of L-Lys(8), and (3) postcyclization addition of the N-terminal thiazoline dipeptide as a single unit. To initiate the synthesis, Fmoc L-Asp(OH)-OAllyl was attached to a PAL resin. The chain of bacitracin A was elaborated in the C-to-N direction by sequential piperidine deprotection/HBTU-mediated coupling cycles with Fmoc D-Asp(OtBu)-OH, Fmoc L-His(Trt)-OH, Fmoc D-Phe-OH, Fmoc L-Ile-OH, Fmoc D-Orn(Boc)-OH, Fmoc L-Lys(Aloc)-OH, Fmoc L-Ile-OH, Fmoc D-Glu(OtBu)-OH, and Fmoc L-Leu-OH. The allyl ester and allyl carbamate protecting groups of L-Asn(12) and L-Lys(8), respectively, were simultaneously and selectively removed by treating the peptide-resin with palladium tetrakis(triphenylphosphine), acetic acid, and triethylamine. Cyclization was effected by PyBOP/HOBT under the pseudo high-dilution conditions afforded by attachment to the solid support. After removal of the N-terminal Fmoc group, the cyclized peptide was coupled with 2-[1'(S)-(tert-butyloxycarbonylamino)-2'(R)-methylbutyl]-4(R)-carboxy-Delta(2)-thiazoline (1). The synthetic peptide was deprotected and cleaved from the solid support under acidic conditions and then purified by reverse-phase HPLC. The synthetic material exhibited an ion in the FAB-MS at m/z 1422.7, consistent with the molecular weight calculated for the parent ion of bacitracin A (MH(+) = C(73)H(84)N(10)O(23)Cl(2), 1422.7 g/mol). It was also indistinguishable from authentic bacitracin A by high-field (1)H NMR and displayed antibacterial activity equal to that of the natural product, thus confirming its identity as bacitracin A. The overall yield for the solid-phase synthesis was 24%.
Online Inquiry
Verification code
Inquiry Basket